Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases

Keyphrases

• Inflammatory Bowel Disease 100%
• Janus Kinase Inhibitors 100%
• Tofacitinib 50%
• Janus Kinase 1 (JAK1) 50%
• Major Adverse Cardiovascular Events 33%
• Small Molecules 33%
• Adverse Events 16%
• Clinical Trials 16%
• Therapeutic Potential 16%
• Pathophysiology 16%
• Cardiovascular Risk 16%
• Moderate to Severe 16%
• Malignancy 16%
• Immunogenicity 16%
• Evidence Support 16%
• U.S. Food 16%
• Hypercholesterolemia 16%
• Long-term Safety 16%
• Long-term Efficacy 16%
• Safety Data 16%
• Short Half-life 16%
• Janus Kinase 2 (JAK2) 16%
• Non-selective 16%
• Active Ulcerative Colitis 16%
• Tyrosine Kinase 16%
• Crohn's Colitis 16%
• Biological Drugs 16%
• Risk Stratification 16%
• Venous Thromboembolism 16%
• Marketing Experiments 16%
• Filgotinib 16%
• Onset of Action 16%
• Treatment Stratification 16%
• Selective Effect 16%
• Potential Adverse Events 16%
• Postmarketing 16%
• Non-response 16%
• JAK3 16%
• Rapid Onset 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Janus Kinase Inhibitor 100%
• Tofacitinib 50%
• Janus Kinase 1 50%
• Adverse Event 33%
• Ulcerative Colitis 33%
• Infection 16%
• Cardiovascular Risk 16%
• Clinical Trial 16%
• Immunogenicity 16%
• Pathophysiology 16%
• Janus Kinase 2 16%
• Hypercholesterolemia 16%
• Biological Product 16%
• Thromboembolism 16%
• Protein Tyrosine Kinase 16%
• Crohn's Disease 16%
• Venous Thromboembolism 16%
• Janus Kinase 3 16%
• Filgotinib 16%
• Cardiovascular Disease 16%